142 related articles for article (PubMed ID: 30595329)
1. Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin.
Abuosa AM; Elshiekh AH; Qureshi K; Abrar MB; Kholeif MA; Kinsara AJ; Andejani A; Ahmed AH; Cleland JGF
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S96-S100. PubMed ID: 30595329
[TBL] [Abstract][Full Text] [Related]
2. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial).
Carrasco R; Ramirez MC; Nes K; Schuster A; Aguayo R; Morales M; Ramos C; Hasson D; Sotomayor CG; Henriquez P; Cortés I; Erazo M; Salas C; Gormaz JG
Trials; 2020 Feb; 21(1):137. PubMed ID: 32019575
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.
Armenian SH; Hudson MM; Chen MH; Colan SD; Lindenfeld L; Mills G; Siyahian A; Gelehrter S; Dang H; Hein W; Green DM; Robison LL; Wong FL; Douglas PS; Bhatia S
BMC Cardiovasc Disord; 2016 Oct; 16(1):187. PubMed ID: 27716152
[TBL] [Abstract][Full Text] [Related]
5. Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin.
Lee M; Chung WB; Lee JE; Park CS; Park WC; Song BJ; Youn HJ
Cancer Med; 2021 Jun; 10(12):3964-3973. PubMed ID: 33998163
[TBL] [Abstract][Full Text] [Related]
6. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
Avila MS; Ayub-Ferreira SM; de Barros Wanderley MR; das Dores Cruz F; Gonçalves Brandão SM; Rigaud VOC; Higuchi-Dos-Santos MH; Hajjar LA; Kalil Filho R; Hoff PM; Sahade M; Ferrari MSM; de Paula Costa RL; Mano MS; Bittencourt Viana Cruz CB; Abduch MC; Lofrano Alves MS; Guimaraes GV; Issa VS; Bittencourt MS; Bocchi EA
J Am Coll Cardiol; 2018 May; 71(20):2281-2290. PubMed ID: 29540327
[TBL] [Abstract][Full Text] [Related]
7. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment.
Azeka E; Franchini Ramires JA; Valler C; Alcides Bocchi E
J Am Coll Cardiol; 2002 Dec; 40(11):2034-8. PubMed ID: 12475466
[TBL] [Abstract][Full Text] [Related]
8. Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity.
Kheiri B; Abdalla A; Osman M; Haykal T; Chahine A; Ahmed S; Osman K; Hassan M; Bachuwa G; Bhatt DL
Am J Cardiol; 2018 Dec; 122(11):1959-1964. PubMed ID: 30292333
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients.
Nousiainen T; Vanninen E; Jantunen E; Remes J; Ritanen E; Vuolteenaho O; Hartikainen J
Clin Sci (Lond); 2001 Dec; 101(6):601-7. PubMed ID: 11724646
[TBL] [Abstract][Full Text] [Related]
10. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial.
Cleland JG; Pennell DJ; Ray SG; Coats AJ; Macfarlane PW; Murray GD; Mule JD; Vered Z; Lahiri A;
Lancet; 2003 Jul; 362(9377):14-21. PubMed ID: 12853194
[TBL] [Abstract][Full Text] [Related]
11. Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up.
Elitok A; Oz F; Cizgici AY; Kilic L; Ciftci R; Sen F; Bugra Z; Mercanoglu F; Oncul A; Oflaz H
Cardiol J; 2014; 21(5):509-15. PubMed ID: 24142687
[TBL] [Abstract][Full Text] [Related]
12. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).
Bosch X; Rovira M; Sitges M; Domènech A; Ortiz-Pérez JT; de Caralt TM; Morales-Ruiz M; Perea RJ; Monzó M; Esteve J
J Am Coll Cardiol; 2013 Jun; 61(23):2355-62. PubMed ID: 23583763
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
Kalay N; Basar E; Ozdogru I; Er O; Cetinkaya Y; Dogan A; Inanc T; Oguzhan A; Eryol NK; Topsakal R; Ergin A
J Am Coll Cardiol; 2006 Dec; 48(11):2258-62. PubMed ID: 17161256
[TBL] [Abstract][Full Text] [Related]
14. Preventive role of carvedilol in adriamycin-induced cardiomyopathy.
Jhorawat R; Kumari S; Varma SC; Rohit MK; Narula N; Suri V; Malhotra P; Jain S
Indian J Med Res; 2016 Nov; 144(5):725-729. PubMed ID: 28361826
[TBL] [Abstract][Full Text] [Related]
15. Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol.
Huang S; Zhao Q; Yang ZG; Diao KY; He Y; Shi K; Shen MT; Fu H; Guo YK
Heart Fail Rev; 2019 May; 24(3):325-333. PubMed ID: 30523513
[TBL] [Abstract][Full Text] [Related]
16. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis.
Yun S; Vincelette ND; Abraham I
Postgrad Med J; 2015 Nov; 91(1081):627-33. PubMed ID: 26399268
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cardioprotective effects of carvedilol in dogs receiving doxorubicin chemotherapy: A prospective, randomized, double-blind, placebo controlled pilot study.
Pino EHM; Weber MN; de Oliveira LO; Vieira LC; Dos Santos KHS; Liu IP; Gomes HM; Trindade-Gerardi AB; Moreira JCF; Gerardi DG
Res Vet Sci; 2021 Mar; 135():532-541. PubMed ID: 33221037
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of beta-blockers on left ventricular dyssynchrony and reverse remodeling in idiopathic dilated cardiomyopathy: A randomized trial of carvedilol and metoprolol.
Kaya MG; Sarli B; Akpek M; Kaya EG; Yarlioglues M; Topsakal R; Lam YY
Cardiol J; 2014; 21(4):434-41. PubMed ID: 24142686
[TBL] [Abstract][Full Text] [Related]
19. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy.
Janbabai G; Nabati M; Faghihinia M; Azizi S; Borhani S; Yazdani J
Cardiovasc Toxicol; 2017 Apr; 17(2):130-139. PubMed ID: 27003392
[TBL] [Abstract][Full Text] [Related]
20. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers.
Lindenfeld J; Robertson AD; Lowes BD; Bristow MR;
J Am Coll Cardiol; 2001 Dec; 38(7):1950-6. PubMed ID: 11738299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
